Reports Q3 revenue $52,000 vs. $20,000 last year. Cash and cash equivalents and marketable securities on September 30, 2024, were $2.9 million, as compared to $1.5 million as of December 31, 2023.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCNX:
- Vaccinex provides update on ActivMAb platform
- Vaccinex to preset new biomarker data on HNSCC
- Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab
- Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study
- Vaccinex files to sell 1.6M shares of common stock for holders
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue